A human MUTYH variant linking colonic polyposis to redox degradation of the [4Fe4S]²⁺ cluster by McDonnell, Kevin J. et al.
1nature research  |  life sciences reporting sum
m
ary
N
ovem
ber 2017
Corresponding author(s): Kevin McDonnell
Life Sciences Reporting Summary
Nature Research wishes to improve the reproducibility of the work that we publish. This form is intended for publication with all accepted life 
science papers and provides structure for consistency and transparency in reporting. Every life science submission will use this form; some list 
items might not apply to an individual manuscript, but all fields must be completed for clarity. 
For further information on the points included in this form, see Reporting Life Sciences Research. For further information on Nature Research 
policies, including our data availability policy, see Authors & Referees and the Editorial Policy Checklist.
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`    Experimental design
1.   Sample size
Describe how sample size was determined. Minimal sample sizes were determined to ensure generation of statistical values for the 
experiments, in line with previously published studies employing these techniques.
2.   Data exclusions
Describe any data exclusions. No data was excluded from study
3.   Replication
Describe the measures taken to verify the reproducibility 
of the experimental findings.
All replication attempts were successful.  Methods sections provides detailed desciptions so 
that other laboratories may successfully repeat experiments
4.   Randomization
Describe how samples/organisms/participants were 
allocated into experimental groups.
Current study is not a randomized control trial and randomization not conventionally 
performed for in vitro experiments in this study. 
5.   Blinding
Describe whether the investigators were blinded to 
group allocation during data collection and/or analysis.
Current study is not a blinded trial and blinding not conventionally performed for in vitro 
experiments in this study.
Note: all in vivo studies must report how sample size was determined and whether blinding and randomization were used.
6.   Statistical parameters 
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the 
Methods section if additional space is needed). 
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same 
sample was measured repeatedly
A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one- or two-sided 
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
Test values indicating whether an effect is present 
Provide confidence intervals or give results of significance tests (e.g. P values) as exact values whenever appropriate and with effect sizes noted.
A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars in all relevant figure captions (with explicit mention of central tendency and variation)
See the web collection on statistics for biologists for further resources and guidance.
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`   Software
Policy information about availability of computer code
7. Software
Describe the software used to analyze the data in this 
study. 
Prism GraphPad
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made 
available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for 
providing algorithms and software for publication provides further information on this topic.
`   Materials and reagents
Policy information about availability of materials
8.   Materials availability
Indicate whether there are restrictions on availability of 
unique materials or if these materials are only available 
for distribution by a third party.
Reagents are available from commercial sources.
9.   Antibodies
Describe the antibodies used and how they were validated 
for use in the system under study (i.e. assay and species).
No antibodies were used in these experiments.
10. Eukaryotic cell lines
a.  State the source of each eukaryotic cell line used. No eukaryotic cell lines were used in these experiments.
b.  Describe the method of cell line authentication used. No eukaryotic cell lines were used in these experiments.
c.  Report whether the cell lines were tested for 
mycoplasma contamination.
No cell lines were used in these experiments.
d.  If any of the cell lines used are listed in the database 
of commonly misidentified cell lines maintained by 
ICLAC, provide a scientific rationale for their use.
No commonly misidentified cell lines were used in these experiments.
`    Animals and human research participants
Policy information about studies involving animals; when reporting animal research, follow the ARRIVE guidelines
11. Description of research animals
Provide all relevant details on animals and/or 
animal-derived materials used in the study.
No animals were used in these experiments.
Policy information about studies involving human research participants
12. Description of human research participants
Describe the covariate-relevant population 
characteristics of the human research participants.
Patient made reference to in current study is enrolled in an IRB-approved cancer genetics 
registry.
